[{"Assets_0_Q2_USD":572055000.0,"CommonStockSharesOutstanding_0_Q2_shares":93321745.0,"NetIncomeLoss_1_Q2_USD":-54724000.0,"NetIncomeLoss_2_Q2_USD":-78402000.0,"StockholdersEquity_0_Q2_USD":490272000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1648000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":2289000.0,"Ticker":"DNLI","CIK":"1714899","name":"DENALI THERAPEUTICS INC.","OfficialName":"Denali Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"3477413158.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20180809"}]